The CHANCE001 study (35) results suggest that TACE plus PD-(L)1 blockade and molecule-targeted treatments could significantly improve PFS, OS, and ORR compared to TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice, with an acceptable safety profile. The gene discussed is CD274; the disease is hepatocellular carcinoma.